Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 7/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294348 | 0.82 | TNF (0.47) | ALDH1A1MGLLCASRTNFKMT2A | |
| SCHEMBL4387357 | 0.73 | ALDH1A1 (0.43) | ALDH1A1CASRPRKDCL3MBTL1SMN1; SMN2 | |
| SCHEMBL12420246 | 0.73 | ALB (0.42) | ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL29482202 | 0.71 | L3MBTL1 (0.62) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4381752 | 0.71 | KDM4E (0.52) | ALDH1A1CASRL3MBTL1MEN1KMT2A | |
| SCHEMBL27598044 | 0.69 | GRM5 (0.42) | ALDH1A1MGLLCASRPRKDCSMN1; SMN2 | |
| SCHEMBL2783127 | 0.69 | ACHE (0.57) | ALDH1A1PRKDCL3MBTL1MEN1KMT2A | |
| SCHEMBL12282147 | 0.67 | KMT2A (0.62) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18116486 | 0.66 | GRM4 (0.54) | ALDH1A1TNFMEN1KMT2A | |
| SCHEMBL18920505 | 0.66 | GRM4 (0.54) | ALDH1A1TNFMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | ALDH1A1 1349/4885MGLL 2636/4885CASR 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.